



Neuroplast opens additional facility to accommodate company growth

Geleen, The Netherlands, 4th of February 2022 – Stem cell biotech Neuroplast has opened a second facility in Maastricht, the Netherlands. This extension to its production facility in Geleen, enables Neuroplast to scale its Neuro-Cells® technology for Traumatic Spinal Cord Injury and other trauma-induced neurological disorders.

The expansion to a second location follows shortly after the biotech announced the successful completion of a clinical Phase I trial of its Neuro-Cells® treatment for Traumatic Spinal Cord Injury and after securing €10M to obtain conditional EMA market approval. At the new site, Neuroplast will develop its own research lab facilities and accommodate its growing number of employees.

Vincent The, Chief Financial Officer of Neuroplast states:

“This new facility gives us lots of flexibility to grow our company and scale our activities. I’m particularly excited about the research labs that will enable us to broaden the applicability of our technology platform and to target therapeutic areas beyond Traumatic Spinal Cord Injury.”

The Neuro-Cells® technology enables production of a medicinal product from the patient’s own stem cells for utilization during the acute phase after sustaining trauma. The treatment aims to save function and optimize recovery potential. The medicinal product is delivered intrathecally, close to the site of injury to maximize effect.

This combination of autologous treatment via intrathecal application in acute setting is what makes Neuro-Cells® different from other stem cell technologies. Further development of the technology platform for multiple indications will be supported from the new facility. The new facility is located close to Neuroplast’s GMP production location on the Brightlands Campus in Geleen.

=== E N D S ===

About Traumatic Spinal Cord Injury

Acute TSCI causes incurable impairment to the spinal cord, affecting approximately 12,000 people across Europe and 17,000 across the USA annually. The damage or trauma interrupts communication of the brain with the body regions below the site of injury. Spinal cord injuries are mainly caused by accidents and - in most of the cases - result in life-long loss of control of motor functions and sensations. After the primary injury to the spinal cord, a cascade of events leads to progressive loss of tissue which may further deteriorate the patient’s prognosis. Current treatment approaches for TSCI are only symptomatic, leaving the underlying pathophysiology unchanged.

TSCI has a serious impact on the quality of life of patients, with severe implications on mobility and loss of independence. In addition, TSCI creates a lifetime financial burden for patients, payors, healthcare systems and societies at large.

About Neuro-Cells®

Neuro-Cells® is a transformative treatment under GMP in the crucial first phase after sustaining TSCI, during which the irreversible impact of TSCI can be radically reduced. It contains non-substantially manipulated bone marrow-derived hematopoietic and mesenchymal stem cells, manufactured from a patient's own bone marrow (donor and receiver are the same person). Inflammatory inducing components and pathogens are removed during this process. The combination of autologous treatment via intrathecal application in acute setting is what makes Neuro-Cells® unique.

About Neuroplast

Neuroplast is a Dutch stem cell technology company focusing on fast-track development programs using autologous cell products for treatment of primarily inflammation-driven neurological disorders, with the aim of giving back perspective to people who suffer from those conditions.

The company was founded in August 2014 by physician Johannes de Munter and neurologist Erik Wolters. Current investors are Lumana Invest, Brightlands Venture Partners, LIOF and the Netherlands Enterprise Agency. Neuroplast is located at the Brightlands Chemelot Campus in The Netherlands and has a second facility in Maastricht.

About Lumana Invest

Investment company Lumana was established by entrepreneurs and unique due to not having a predetermined investment horizon. The Lumana founders showcase strong commitment to their portfolio companies by actively supporting management in strategic decision making.

About Brightlands Venture Partners

Brightlands Venture Partners is the fund manager of BVP Fund IV and is a so-called ecosystem investor. BVP invests in companies benefiting from and contributing to the Brightlands campuses in the south of The Netherlands. Other funds under management are Chemelot Ventures, Brightlands Agrifood Fund and Limburg Ventures. BVP Fund IV focuses on sustainability and health and is the successor fund of the 2014 vintage Chemelot Ventures; together the funds have made over 40 investments.

About LIOF

LIOF is the regional development agency for Limburg and supports innovative entrepreneurs with advice, network and financing. Together with entrepreneurs and partners, LIOF is working towards a smarter, more sustainable and healthier Limburg by focusing on the transitions of energy, circularity, health and digitalization.

About The Netherlands Enterprise Agency

The Netherlands Enterprise Agency operates under the auspices of the Dutch Ministry of Economic Affairs and Climate Policy. It facilitates entrepreneurship, improves collaborations, strengthens positions and helps realize national and international ambitions with funding, networking, know-how and compliance with laws and regulations.

Forward looking statements

All statements other than statements of historical facts, including the statements about the clinical and therapeutic potential and future clinical milestones of Neuro-Cells[®], the indications we intend to pursue and our possible clinical or other business strategies, and the timing of these events, are forward-looking statements. Forward-looking statements can be identified by terms such as “believes”, “expects”, “plans”, “potential”, “would” or similar expressions and the negative of those terms. These forward-looking statements are based on our management’s current beliefs and assumptions about future events and on information currently available to management. Neuroplast B.V. does not make any representation or warranty, express or implied, as to the improper use of this article, accuracy, completeness or updated status of above-mentioned statements. Therefore, in no case whatsoever will Neuroplast B.V. be legally liable or liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

In case of any further questions, please contact:

Neuroplast

Johannes de Munter, CEO

T: +31 (0)85 076 1000

E: h.demunter@@neuroplast.com